ICU Medical, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2024; comparison is with Q1 2023. ICU Medical develops and sells medical products across Consumables, Infusion Systems and Vital Care, including infusion pumps and supplies, vascular access products, IV solutions and critical-care products. Results are unaudited.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $566.7 million | $568.6 million |
| Gross profit / margin | $185.2 million / 32.7% | $192.0 million / 33.8% |
| Operating income (loss) | $(10.7) million | $9.4 million |
| Net income (loss) | $(39.5) million | $(9.8) million |
| Diluted loss per share | $(1.63) | $(0.41) |
| Operating cash flow | $45.8 million | $41.2 million |
| Capital expenditures | $15.9 million | $14.2 million |
At March 31, 2024, cash and cash equivalents were $251.4 million, with no short-term investments. Current assets were $1.188 billion and current liabilities $455.4 million. Long-term debt carrying value was $1.617 billion, including $51.0 million current; aggregate loan principal was approximately $1.635 billion. The $500 million revolving facility had no borrowings. Cash and short-term investments declined $3.3 million from year-end. Management says existing cash, expected operating cash flow, the receivables purchase facility and available credit should fund requirements for the next 12 months.
Material changes versus the prior period
- Revenue was down 0.4%. Consumables increased 3.4% to $244.1 million; Infusion Systems decreased 2.7% to $157.3 million as reported, but was up 0.4% on a constant-currency basis; Vital Care decreased 3.2% to $165.3 million.
- Gross margin fell 1.1 percentage points. Management cited lower manufacturing absorption and foreign exchange, particularly the stronger Mexican peso; lower remediation spending, price increases and reduced supply-chain and freight costs partly offset the decline.
- Operating results shifted from $9.4 million income to a $10.7 million loss. SG&A rose 3.3% to $157.7 million, R&D rose 10.1% to $21.8 million, and restructuring, strategic transaction and integration expenses rose to $16.1 million from $11.0 million.
- Net loss widened to $39.5 million. Net interest expense increased to $23.8 million from $22.5 million, while other expense increased to $2.3 million, mainly reflecting foreign-exchange losses.
- Operating cash flow increased to $45.8 million. Working-capital movements included lower receivables and inventory, partly offset by a $16.5 million reduction in accrued liabilities. Debt principal repayments were $12.8 million.
Outlook, commentary and notable risks
- Management maintained its previously disclosed 2024 capital expenditure estimate of $90 million to $110 million and its estimate of $90 million to $110 million for other future capital investments, including restructuring/integration and quality-compliance spending.
- Management expects supply-chain pressure to lessen and inflation to continue subsiding in 2024, but freight costs remain volatile; higher interest rates and foreign-exchange effects are expected to continue affecting results. These are expectations, not guarantees.
- Debt is largely variable-rate despite interest-rate hedges. The filing estimates a 1 percentage-point SOFR change would alter annual term-loan interest expense by approximately $16.4 million. The company was compliant with financial covenants at quarter-end; the maximum secured leverage ratio tightens after June 30, 2024.
- Accrued field-service corrective-action costs were approximately $54.8 million, of which about $52.3 million related to Smiths Medical and its FDA Warning Letter-related remediation. Actual costs may differ from estimates, including if additional corrective actions are needed.
- Other notable items include a $10.1 million tax expense from a valuation allowance against certain U.S. deferred tax assets, partly offset by a $2.3 million excess tax benefit; $10.8 million of Smiths Medical integration and transaction expenses; and $175.7 million of receivables sold under an uncommitted purchase program during the quarter.
- Management reported no material change to previously disclosed risk factors and no material adverse impact expected from unsettled routine legal proceedings. Key risks include demand and competition, supplier or manufacturing disruption, quality and regulatory matters, foreign exchange, interest rates, acquisition integration and substantial debt.
Important facts for investors to verify
- Whether revenue and gross-margin trends improve, including the effects of production volumes, Mexican peso movements, pricing and lower freight costs.
- Progress and remaining cost exposure for Smiths Medical integration, FDA-related corrective actions and other quality-compliance commitments.
- Debt reduction, variable-rate exposure, covenant headroom and the availability and terms of the uncommitted receivables purchase program.
- Whether future taxable income supports deferred tax assets and the current valuation-allowance position.
- Concentration and distributor exposure: Medline accounted for approximately 17% of Q1 revenue, versus 15% a year earlier.